Compare Mesoblast Limited (MESO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs GeneDx Holdings Corp — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| MESO | WGS | |
|---|---|---|
Market Cap | $2.17B | $1.80B |
Sector | Technology | Technology |
52-Week High | $20.96 | $167.51 |
52-Week Low | $12.88 | $34.51 |
Enterprise Value | $2.17B | $1.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
